Dr. Christine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
400 Parnassus Ave
San Francisco, CA 94143Phone+1 415-353-2459Fax+1 415-353-2898
Summary
- I completed completed Neurology Residency at UCSF in 1995 and then conducted research fellowship in in synaptic plasticity until 1999.
Since then, I have developed far ranging interests in Parkinson’s disease (PD) including: 1) discovery of the risk factors for the development of PD 2) identification of factors that affect PD progression, and 3) improving PD treatments.
My research has included participation in both medical and surgical treatment studies and I have been involved in a study of novel biomarkers for PD. I am an investigator in a several phase 1 studies and one phase 2 gene therapy studies for advanced Parkinson’s disease. I am also studying the relationship of low vitamin B12 status with the development of gait impairment in PD.
My goals are to 1) reduce the incidence of PD, 2) slow its progression when it is diagnosed, and 3) to developed more effective treatments for it.
Education & Training
University of California (San Francisco)Residency, Neurology, 1992 - 1995- University of California (San Francisco)Internship, Internal Medicine, 1991 - 1992
Weill Cornell MedicineClass of 1991
Certifications & Licensure
CA State Medical License 1993 - 2025- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- GDNF Gene Therapy for Parkinson's Disease Start of enrollment: 2020 Apr 01
- A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD Start of enrollment: 2022 Aug 03
Roles: Principal Investigator
Publications & Presentations
PubMed
- 296 citationsAcidosis reduces NMDA receptor activation, glutamate neurotoxicity, and oxygen-glucose deprivation neuronal injury in cortical cultures.Rona G. Giffard, Hannelore Monyer, Chadwick W. Christine, Dennis W. Choi
Brain Research. 1990-01-08 - 54 citationsAmphetamine exposure is elevated in Parkinson's disease.Elisabeth R. Garwood, Wosen Bekele, Charles E. McCulloch, Chadwick W. Christine
Neurotoxicology. 2006-12-01 - 258 citationsActivity differentially regulates the surface expression of synaptic AMPA and NMDA glutamate receptorsDmitri V. Lissin, Stephen N. Gomperts, Reed C. Carroll, Chadwick W. Christine, Daniel Kalman
Proceedings of the National Academy of Sciences of the United States of America. 1998-06-09
Press Mentions
Low Levels of Vitamin B12 May Worsen Walking, Cognition in Parkinson’s PatientsMarch 9th, 2018
Low Levels of Vitamin B12 in Parkinson's Contributes to DisabilitySeptember 29th, 2015
Professional Memberships
- Fellow
- International Parkinson and Movement Disorder SocietyMember
- American Neurological AssociationFellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
